Eli Lilly and Company (LLY)
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
Some people make it a New Year's resolution to improve their finances by investing in stocks. It's a laudable goal, and to get started, it's crucial to pick stocks that have the tools to perform well for decades to come.
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
It's not the biggest publicly traded company in the world right now. That honor still belongs to Apple with a market cap if just under $3.5 trillion.
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's recent climb.
Why Eli Lilly Stock Topped the Market Today
Eli Lilly (LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival.
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds up well at these companies regardless of general economic conditions. But certain pharmaceutical and biotech stocks stand out from time to time, behaving more like growth players with soaring revenue and stock performance.
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
Eli Lilly (LLY) closed at $753.98 in the latest trading session, marking a +1.57% move from the prior day.
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
Eli Lilly (NYSE: LLY) doesn't really need much of an introduction.
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Shares of Eli Lilly and Company LLY are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected.
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. What It Means for the Stocks.
Weight-loss medications have exploded in popularity but the health-benefits go beyond obesity.
Eli Lilly: Market Overreacted
Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY still projects 32% growth for 2024, underscoring strong fundamentals and an impressive growth trajectory. The company's diverse portfolio, including Mounjaro and Zepbound, shows broad growth, with significant contributions from oncology and other therapeutic areas.
Should You Buy the Dip in Eli Lilly Stock Right Now?
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (LLY -4.21%). At one point, share prices had gained as much as 65% on the year.
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (LLY -4.21%) could do no wrong. Unfortunately, the good times didn't last very long.
